Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQ30X2)

Drug Name
HQP1351 Drug Info
Synonyms
GZD824; 1257628-77-5; GZD-824; 3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; UNII-KV1M7Q3CBP; KV1M7Q3CBP; 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide; CHEMBL2316582; Benzamide, 4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-; HQP-1351; olverembatinib; 4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}-3-(2-{1H-pyrazolo[3,4-b]pyridin-5-yl}ethynyl)benzamide; Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)-; HQP1351 free base; HQP-1351 free base; SCHEMBL3424528; GTPL10630; EX-A829; AOB87323; BCP07502; BDBM50425780; ZINC95594040; AKOS026750647; CS-1444; SB16617; compound 10a [PMID: 23301703]; NCGC00351607-06; AK547162; AS-75170; HY-15666; D-824; FT-0700150; A16264; W-6136; J-690110; 4-Methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1H-pyrazolo(3,4-b)pyridin-5-yl)ethynyl)benzamide
Cross-matching ID
PubChem CID
51038269
ChEBI ID
CHEMBL2316582
CAS Number
CAS 1257628-77-5
TTD Drug ID
DH5RN1

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glycine, serine and threonine metabolism 2.44 0.00e+0 31/40 (77.5%) PHGDH;PSAT1;CBS;...
Cysteine and methionine metabolism 2.24 0.00e+0 43/50 (86%) PHGDH;PSAT1;CBS;...
Glyoxylate and dicarboxylate metabolism 2.00 2.73e-3 23/30 (76.67%) SHMT2;PCCA;SHMT1;...
Alanine, aspartate and glutamate metabolism 1.95 4.10e-3 27/37 (72.97%) ASNS;ASS1;GLS2;...
Propanoate metabolism 1.90 4.92e-3 30/34 (88.24%) PCCA;PCCB;ALDH6A1;...
One carbon pool by folate 1.84 1.09e-2 15/20 (75%) SHMT2;TYMS;MTHFD2;...
Porphyrin and chlorophyll metabolism 1.79 1.88e-2 23/43 (53.49%) BLVRB;HMOX1;HMBS;...
Glutathione metabolism 1.78 1.95e-2 43/57 (75.44%) CHAC1;PGD;GCLM;...
Butanoate metabolism 1.77 1.91e-2 23/28 (82.14%) HADH;BDH1;ACSM3;...
RNA degradation 1.71 3.69e-2 53/79 (67.09%) TOB1;PFKM;LSM2;...
Citrate cycle (TCA cycle) 1.70 3.73e-2 30/30 (100%) PCK2;SDHC;IDH1;...
Arginine biosynthesis 1.70 3.56e-2 17/22 (77.27%) ASS1;GLS2;GOT1;...
Folate biosynthesis 1.69 3.28e-2 23/26 (88.46%) AKR1C3;MOCOS;PCBD1;...
DNA replication 1.66 4.40e-2 34/36 (94.44%) PRIM1;POLD2;POLE2;...
Inflammatory bowel disease -1.61 3.46e-2 58/65 (89.23%) IL18R1;STAT6;GATA3;...
NF-kappa B signaling pathway -1.65 2.62e-2 90/104 (86.54%) TNFRSF11A;TRAF6;MYD88;...
Chagas disease -1.66 2.68e-2 93/102 (91.18%) TRAF6;MYD88;MAPK13;...
C-type lectin receptor signaling pathway -1.66 2.69e-2 93/104 (89.42%) CYLD;NFKB1;AKT1;...
Hematopoietic cell lineage -1.67 2.66e-2 90/99 (90.91%) CD3E;ANPEP;ITGA1;...
Apelin signaling pathway -1.67 2.77e-2 117/137 (85.4%) CCND1;RPS6KB1;PIK3C3;...
TNF signaling pathway -1.67 2.79e-2 103/112 (91.96%) NOD2;MAPK13;DNM1L;...
Tight junction -1.69 2.11e-2 130/169 (76.92%) GATA4;PARD3;PPP2CA;...
MAPK signaling pathway -1.70 2.04e-2 272/294 (92.52%) TRAF6;MYD88;NRAS;...
Pathogenic Escherichia coli infection -1.74 1.32e-2 152/197 (77.16%) ARPC3;ARPC5L;NCL;...
Axon guidance -1.75 1.15e-2 151/182 (82.97%) SLIT1;RND1;MAPK1;...
Yersinia infection -1.76 1.15e-2 120/137 (87.59%) CHUK;MAPK1;CRK;...
Colorectal cancer -1.76 1.22e-2 84/86 (97.67%) CCND1;RPS6KB1;TCF7L1;...
AGE-RAGE signaling pathway in diabetic complications -1.78 8.82e-3 97/100 (97%) AGER;EDN1;MAPK3;...
Fc gamma R-mediated phagocytosis -1.80 9.37e-3 79/97 (81.44%) ARPC1A;PIP5K1A;SYK;...
Endocytosis -1.82 9.22e-3 198/252 (78.57%) STAM2;ARPC3;DNM1;...
Regulation of actin cytoskeleton -1.84 9.06e-3 185/218 (84.86%) CDC42;ITGA1;IQGAP2;...
Salmonella infection -1.88 3.55e-3 198/249 (79.52%) ARPC3;PIK3C3;ARPC5L;...
Vibrio cholerae infection -1.88 3.84e-3 44/50 (88%) TJP2;TCIRG1;ATP6V0C;...
Rheumatoid arthritis -1.89 3.14e-3 78/93 (83.87%) TNFSF11;TEK;TLR4;...
Arrhythmogenic right ventricular cardiomyopathy -1.93 3.46e-3 70/77 (90.91%) TCF7L1;TCF7;SGCB;...
Proteoglycans in cancer -1.94 3.84e-3 172/205 (83.9%) ITPR3;RDX;MYC;...
Focal adhesion -1.98 4.32e-3 180/201 (89.55%) PIP5K1A;PAK2;PDPK1;...
Hippo signaling pathway -1.98 4.94e-3 120/186 (64.52%) PARD3;CSNK1E;PPP2CA;...
Epithelial cell signaling in Helicobacter pylori infect... -1.99 5.76e-3 62/70 (88.57%) MAPK11;F11R;JAM2;...
Adherens junction -2.00 4.61e-3 63/71 (88.73%) PARD3;PTPRJ;MAP3K7;...
Bacterial invasion of epithelial cells -2.07 2.88e-3 59/77 (76.62%) ARHGAP10;ILK;ARPC3;...
Amoebiasis -2.09 3.84e-3 99/102 (97.06%) CD1B;CD1A;CSF2;...
ECM-receptor interaction -2.15 5.76e-3 80/88 (90.91%) ITGA10;CD44;VWF;...
IL-17 signaling pathway -2.21 0.00e+0 84/94 (89.36%) MAPK13;MUC5B;MMP3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H